Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

1.5K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.5K
Imbalances in Cardiac Output01:26

Imbalances in Cardiac Output

1.3K
The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
1.3K
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

500
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
500

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Essential Role for Telomeric Repeat-Binding Factor 2 in Cardiac Development and Function.

FASEB bioAdvances·2026
Same author

Adropin protects against cardiac remodeling and metabolic dysfunction in a male mouse HFpEF model.

Clinical science (London, England : 1979)·2026
Same author

Lower expression of BRCA1 in cardiomyoblast alters the expression of apoptotic, inflammatory and metabolic pathway genes, and enhances catecholamine-induced hypertrophic response.

Gene·2026
Same author

GCN5L1-Mediated Lysine Acetylation Regulates Mitochondrial Bioenergetics and Redox Homeostasis in the Aged Heart.

Antioxidants (Basel, Switzerland)·2026
Same author

Lipid stress evolved, microbiome-based probiotics reduce lipid uptake in mice.

Bioengineering & translational medicine·2026
Same author

Author Correction: Tissue-resident macrophage survival depends on mitochondrial function regulated by SerpinB2 in chronic inflammation.

Nature communications·2026

Related Experiment Video

Updated: May 27, 2025

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF
03:42

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Published on: March 29, 2024

1.4K

Cardiac-specific GCN5L1 deficiency promotes MASLD in HFpEF.

Paramesha Bugga1,2, Bellina A S Mushala1,2, Michael W Stoner1,2

  • 1Vascular Medicine Institute, University of Pittsburgh.

Biorxiv : the Preprint Server for Biology
|February 20, 2025
PubMed
Summary

Heart failure with preserved ejection fraction (HFpEF) and metabolic dysfunction-associated liver disease (MASLD) are linked. A cardiac metabolic defect involving GCN5L1 protein drives liver issues in HFpEF patients.

Keywords:
BCAAsBCKAsGCN5L1HFpEFHeartLiverMASLD

More Related Videos

Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model
05:58

Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model

Published on: April 18, 2025

113
Analyzing Oxygen Consumption Rate in Primary Cultured Mouse Neonatal Cardiomyocytes Using an Extracellular Flux Analyzer
11:26

Analyzing Oxygen Consumption Rate in Primary Cultured Mouse Neonatal Cardiomyocytes Using an Extracellular Flux Analyzer

Published on: February 13, 2019

8.6K

Related Experiment Videos

Last Updated: May 27, 2025

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF
03:42

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Published on: March 29, 2024

1.4K
Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model
05:58

Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model

Published on: April 18, 2025

113
Analyzing Oxygen Consumption Rate in Primary Cultured Mouse Neonatal Cardiomyocytes Using an Extracellular Flux Analyzer
11:26

Analyzing Oxygen Consumption Rate in Primary Cultured Mouse Neonatal Cardiomyocytes Using an Extracellular Flux Analyzer

Published on: February 13, 2019

8.6K

Area of Science:

  • Cardiology
  • Metabolic Diseases
  • Hepatology

Background:

  • Cardiometabolic heart failure with preserved ejection fraction (HFpEF) is increasingly prevalent.
  • Current HFpEF treatments manage comorbidities like obesity, diabetes, and hypertension.
  • Existing research explores how liver disease impacts the heart in metabolic syndrome.

Purpose of the Study:

  • To investigate the relationship between cardiac metabolism and liver disease in HFpEF.
  • To identify novel molecular mechanisms linking HFpEF and metabolic dysfunction-associated liver disease (MASLD).
  • To challenge the prevailing view of liver-to-heart disease progression.

Main Methods:

  • Analysis of cardiac metabolism in HFpEF models.
  • Investigation of the role of the mitochondrial protein GCN5L1.
  • Assessment of GCN5L1's impact on liver pathology, including hepatic steatosis and MASLD.

Main Results:

  • A defect in cardiac metabolism, specifically involving the mitochondrial protein GCN5L1, was identified in HFpEF.
  • This cardiac metabolic defect was found to drive hepatic steatosis and MASLD.
  • This study presents the first evidence of a heart-to-liver disease mechanism in HFpEF.

Conclusions:

  • Cardiac GCN5L1 deficiency contributes to liver disease development in HFpEF.
  • This finding offers a new perspective on the interplay between cardiac and liver metabolic health.
  • Targeting cardiac metabolism may offer novel therapeutic strategies for HFpEF and associated MASLD.